Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience

Serhat Özçelik; Mehmet Çelik; Aşkı Vural; Bünyamin Aydın; Melike Özçelik; Hulya Gozu

doi:10.5114/aoms.2020.93264

Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience

Arch Med Sci. 2020 Feb 25;17(1):1-8. doi: 10.5114/aoms.2020.93264. eCollection 2021.

Authors

Serhat Özçelik¹, Mehmet Çelik², Aşkı Vural³, Bünyamin Aydın¹, Melike Özçelik⁴, Hulya Gozu⁵

Affiliations

¹ Department of Endocrinology and Metabolism, Adıyaman Training and Research Hospital, Adıyaman, Turkey.
² Department of Internal Medicine, Division of Endocrinology and Metabolism, Antalya Kepez State Hospital, Kepez, Turkey.
³ Division of Internal Medicine, Adıyaman Training and Research Hospital, Adıyaman, Turkey.
⁴ Department of Internal Diseases, Umraniye Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
⁵ Department of Endocrinology and Metabolism, Marmara University Training and Research Hospital, Turkey.

Abstract

Introduction: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus.

Material and methods: In this 12-week study, patients receiving twice-daily premixed insulin therapy in group 1 (n = 55) were switched to twice-daily IDegAsp. In group 2 (n = 60), patients on intensive insulin therapy were switched to IDegAsp injected twice a day. Inter- and intragroup comparisons were made.

Results: A total of 115 patients were included in the study. There was a significant improvement in glycaemic control, median daily total insulin dose, body mass, body mass index, and hypoglycaemic events in group 1 and group 2 with the switch to IDegAsp (p < 0.05). The decrease in median daily total insulin dose requirement in group 2 was higher than that of group 1 (p = 0.001). There was no difference between groups in terms of other parameters (p > 0.05).

Conclusions: The current analysis indicates that IDegAsp treatment improves outcomes, with the most notable differences observed in daily total insulin requirement, body mass, and hypoglycaemia.

Keywords: co-formulation; degludec; intensive; premixed.